Compare Progressive Corp (PGR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs TransMedics Group Inc — how do they compare? Progressive Corp trades at $215.8 (market cap $125.23B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: Progressive Corp is far larger — about 41.7× TransMedics Group Inc's market cap, and Progressive Corp pays a 0.19% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PGR | TMDX | |
|---|---|---|
Market Cap | $125.23B | $3.00B |
Sector | Financials | Technology |
52-Week High | $248.80 | $150.42 |
52-Week Low | $190.40 | $61.99 |
Enterprise Value | $133.44B | $3.39B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive (PGR) trades at $214.9, down 1.85% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.78, net income margin of 12.85%, and ROE of 34.94%, supported by revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q4 2025 and Q2 2026, but missed in Q1 2026. News highlights competition in auto insurance and telematics advantages.
Outlook is mixed: analyst consensus targets $231.18 with 38.1% buy ratings, but technical weakness and competitive pressures pose risks. Investment opportunity lies in valuation discounts and operational strength, though expense increases and market volatility require caution.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
